Exclusive: Breaking up immune webs called NETs may offer new way to treat autoimmune disease, early data suggest Neutrolis tests enzyme therapy targeting neutrophil extracellular traps (NETs) in Phase 1 trial, showing promise for autoimmune diseases. Drug cleared symptoms in teen with DNASE1L3 deficiency.

DNA-chopping enzyme that breaks up NETs (neutrophil extracellular traps) may offer new way to fight autoimmune disease, early data from #Neutrolis suggest. The company has raised $50M from Morningside. Read more in my latest exclusive for @endpts.com. #ACR2025 endpoints.news/dna-chopping...